Vivid News Wave

Wedbush Reiterates Outperform Rating for AXT (NASDAQ:AXTI)


Wedbush Reiterates Outperform Rating for AXT (NASDAQ:AXTI)

AXT (NASDAQ:AXTI - Get Free Report)'s stock had its "outperform" rating reaffirmed by investment analysts at Wedbush in a research report issued on Friday,RTT News reports. They presently have a $4.50 price target on the semiconductor company's stock, down from their previous price target of $5.50. Wedbush's price target points to a potential upside of 184.81% from the company's previous close.

Several other brokerages have also commented on AXTI. Northland Securities dropped their price target on shares of AXT from $6.00 to $5.00 and set an "outperform" rating on the stock in a research note on Friday, November 1st. B. Riley reiterated a "buy" rating and set a $6.00 price objective (up previously from $5.50) on shares of AXT in a research note on Friday. Finally, Needham & Company LLC reiterated a "buy" rating and set a $5.00 price objective on shares of AXT in a research note on Friday. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, AXT has a consensus rating of "Moderate Buy" and a consensus price target of $5.10.

Get Our Latest Stock Analysis on AXTI

Shares of NASDAQ:AXTI traded down $0.71 during trading hours on Friday, hitting $1.58. The stock had a trading volume of 6,654,761 shares, compared to its average volume of 411,068. The stock's fifty day simple moving average is $2.17 and its 200 day simple moving average is $2.29. AXT has a 1-year low of $1.56 and a 1-year high of $5.64. The firm has a market capitalization of $70.71 million, a price-to-earnings ratio of -5.64 and a beta of 2.08.

AXT (NASDAQ:AXTI - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The semiconductor company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.08). AXT had a negative net margin of 11.70% and a negative return on equity of 5.27%. The firm had revenue of $25.11 million during the quarter, compared to analyst estimates of $23.94 million. As a group, research analysts anticipate that AXT will post -0.12 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the stock. Canandaigua National Bank & Trust Co. acquired a new position in AXT in the fourth quarter worth approximately $28,000. Bleakley Financial Group LLC acquired a new position in AXT in the fourth quarter worth approximately $29,000. Atlas Brown Inc. acquired a new position in AXT in the fourth quarter worth approximately $42,000. Virtu Financial LLC acquired a new position in AXT in the fourth quarter worth approximately $54,000. Finally, Jane Street Group LLC acquired a new position in AXT in the fourth quarter worth approximately $60,000. Institutional investors and hedge funds own 49.52% of the company's stock.

AXT, Inc designs, develops, manufactures, and distributes compound and single element semiconductor substrates. The company offers indium phosphide for use in data center connectivity using light/lasers, high-speed data transfer in data centers, 5G communications, fiber optic lasers and detectors, consumer devices, passive optical networks, silicon photonics, photonic integrated circuits, thermo-photovoltaics, RF amplifier and switching, infrared light-emitting diode (LEDS) motion control, lidar for robotics and autonomous vehicles, and infrared thermal imaging.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AXT wasn't on the list.

While AXT currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

Previous articleNext article

POPULAR CATEGORY

corporate

9347

tech

9208

entertainment

11589

research

5322

misc

12268

wellness

9377

athletics

12220